Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study-Reference-Cited by-同舟云学术

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

Published:2022-06-17 Issue: Volume: Page:
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Trippett Tanya,Toledano Helen,Campbell Hewson Quentin,Verschuur Arnauld,Langevin Anne-Marie,Aerts Isabelle,Howell Lisa,Gallego Soledad,Rossig Claudia,Smith Amy,Patel Darshak,Pereira Leonardo R.,Cheeti Sravanthi,Musib Luna,Hutchinson Katherine E.,Devlin Clare,Bernardi Ronald,Geoerger Birgit

Funder

F. Hoffmann-La Roche Ltd/Genentech, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-022-00888-9.pdf

Reference28 articles.

1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.

2. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218:172–81.

3. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA. 2013;110:5957–62.